Jordyn Sava is an editor for Targeted Oncology.
Zolbetuximab Combo Meets Efficacy End Points in CLDN18.2+, HER2- Gastric/GEJ Cancers
December 19th 2022The GLOW trial of zolbetuximab plus capecitabine and oxaliplatin showed statistically significant progression-free and overall survival rates in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Dostarlimab Extends PFS and Elicits Better Responses vs Pembrolizumab in NSCLC
December 8th 2022Frontline treatment with dostarlimab and chemotherapy reduced the risk of disease progression and led to better objective response rates and progression-free survival vs pembrolizumab in patients with metastatic non-squamous non–small cell lung cancer.
ECHELON-1 Trial of Brentuximab Vedotin Improves OS in Classical Hodgkin Lymphoma
December 7th 2022In an interview with Targeted Oncology, David J. Straus, MD, discussed the newest data of the ECHELON-1 trial which he presented at the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.
Eprenetapopt/Azacitidine After HCT is Positive in TP53-Mutated AML and MDS
December 2nd 2022Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic stem-cell transplant induced encouraging relapse-free and overall survival in patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome.
Daratumumab With Bortezomib and Dexamethasone Improves Survival in RRMM
December 2nd 2022Patients with multiple myeloma administered daratumumab in combination with bortezomib and dexamethasone demonstrated improvements in overall survival compared with those given bortezomib and dexamethasone alone.
UCART19 Shows Promising Safety/Efficacy in Adult Patients With B-Cell ALL
November 30th 2022Findings from the phase 1 CALM study evaluating the allogeneic genome-edited anti-CD19 chimeric antigen receptor T-cell product UCART19 show it can be safely used for patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Ultra-Low Dose of Radiation Shows Promise in Orbital Indolent B-Cell Lymphomas
November 28th 2022In an interview with Targeted Oncology, Chelsea C. Pinnix discussed the results of a phase 2 study and how these promising results will shift the treatment paradigm of patients with orbital indolent B-cell lymphoma.
Pralsetinib Shows Positive Phase 1/2 Results in RET Fusion+ NSCLC
November 26th 2022Updated analysis from the phase 1/2 ARROW study evaluating pralsetinib in patients with RET fusion-positive non–small cell lung cancer showed the agent to be well tolerated and to elicit clinical activity at a dose of 400 mg daily.
Afami-cel Elicits Durable Responses With Tolerable Safety in Pre-Treated Synovial Sarcoma
November 22nd 2022With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.